| human | Q5 |
| P496 | ORCID iD | 0000-0003-2864-4345 |
| P69 | educated at | Royal College of Pathologists of Australasia | Q7373984 |
| P108 | employer | Children's Medical Research Institute | Q5098159 |
| P106 | occupation | researcher | Q1650915 |
| Q39917230 | A class discovery and class prediction approach to histopathological classification of mammographic screen detected columnar cell lesions of the breast |
| Q35755874 | A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer |
| Q64458508 | Abstract 5493: Genome-wide study of carboplatin and paclitaxel disposition in ovarian cancer patients |
| Q34480599 | Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource |
| Q34871343 | Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer |
| Q33781403 | Bayes analysis provides evidence of pathogenicity for the BRCA1 c.135-1G>T (IVS3-1) and BRCA2 c.7977-1G>C (IVS17-1) variants displaying in vitro splicing results of equivocal clinical significance |
| Q44922994 | CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. |
| Q85273990 | Characteristics of HER2-positive breast cancer diagnosed following the introduction of universal HER2 testing |
| Q35891162 | Common breast cancer susceptibility loci are associated with triple-negative breast cancer |
| Q35794653 | Common germline polymorphisms associated with breast cancer-specific survival |
| Q33851325 | Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesis |
| Q37244666 | DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast |
| Q28305621 | Development of a data entry auditing protocol and quality assurance for a tissue bank database |
| Q37753978 | Diagnostic evaluation of papillary lesions of the breast on core biopsy |
| Q58024482 | Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring--The TADE Study |
| Q38213598 | Electronic biorepository application system: web-based software to manage receipt, peer review, and approval of researcher applications to a biobank. |
| Q44845076 | Expression of progesterone receptor A and B isoforms in low-grade endometrial stromal sarcoma |
| Q43758408 | Familial concordance of breast cancer pathology as an indicator of genotype in multiple-case families |
| Q34378972 | Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade |
| Q24622610 | Genome-wide association studies identify four ER negative-specific breast cancer risk loci |
| Q48171906 | Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer |
| Q50848684 | Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver. |
| Q37893534 | HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis |
| Q34173413 | HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer |
| Q45215061 | Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer |
| Q38027578 | High-risk estrogen-receptor-positive breast cancer: identification and implications for therapy |
| Q81186342 | Histopathological features of 'BRCAX' familial breast cancers in the kConFab resource |
| Q43236099 | Hormone-responsive model of primary human breast epithelium |
| Q36014067 | Identification of novel genetic markers of breast cancer survival |
| Q38084286 | Ki67 and proliferation in breast cancer |
| Q57287321 | MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma |
| Q57635918 | Molecular Grading of Ductal Carcinoma In situ of the Breast |
| Q51930299 | Morphology of breast cancer as a means of triage of patients for BRCA1 genetic testing. |
| Q30374367 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. |
| Q33586121 | Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer |
| Q46312557 | Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification |
| Q36583004 | Prediction of breast cancer risk based on profiling with common genetic variants |
| Q48703561 | Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. |
| Q48163436 | Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study |
| Q60662123 | Progesterone Receptors in Normal and Neoplastic Breast |
| Q42449247 | Prohibitin expression is associated with high grade breast cancer but is not a driver of amplification at 17q21.33. |
| Q35155449 | Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia |
| Q39574555 | Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome |
| Q98177089 | Strategies to enable large-scale proteomics for reproducible research |
| Q35048057 | Targeting molecular mechanisms in cancer. |
| Q28258903 | Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer |
Search more.